BioInvent Publication in JECCR: Tailored FcγR Blockade with BI-1206 ...
(PR-inside.com) LUND, SE / ACCESS Newswire / July 28, 2026 / BioInvent International (STO:BINV) Preclinical proof-of-concept data support two distinct FcγR-blockade strategies to enhance cancer antibody therapies and overcome resistance BI-1206 boosts αPD-1 antibody activity by protecting effector CD8+ T cells from mac…
Short extract only — this publisher licenses its text. Read the full release at the source.
Free plan · Plus CA$29 or Pro CA$99/month


